Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
Patent CN114045271B reveals high-efficiency biocatalysis for Atazanavir intermediates. Discover cost reduction and supply chain reliability with immobilized enzyme technology.
Patent CN113652408A reveals a novel carbonyl reductase mutant for efficient (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering superior yield and green manufacturing advantages.
Patent CN102876734B details a novel carbonyl reductase for high-purity chiral alcohol production, offering significant cost and supply chain advantages for API intermediates.
Patent CN117210426A reveals enzyme mutant for chiral alcohol synthesis. Offers cost reduction in API manufacturing and reliable pharmaceutical intermediate supplier solutions.
Patent CN104099305A reveals stable CgKR1 mutants for Clopidogrel intermediates. Enhances purity and supply chain reliability for global pharmaceutical manufacturing.
Patent CN101962661B reveals high-efficiency carbonyl reductase for statin intermediates. Offers superior yield and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN108753851B details a novel ChKRED12 enzyme method for producing high-purity chiral 1,2-diols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN118421578A reveals high-efficiency carbonyl reductase for Montelukast intermediate. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN111172124A reveals a novel carbonyl reductase mutant enabling high-concentration synthesis. Discover cost-effective supply chain solutions for this key pharma intermediate.
Patent CN107653238A reveals immobilized carbonyl reductase cells for high-yield statin intermediate production, offering significant supply chain stability and cost reduction advantages.
Patent CN113322291A details an enzymatic route for high-purity chiral amino alcohols, offering cost-effective solutions for veterinary antibiotic manufacturing.
Patent CN115948356B reveals high-efficiency carbonyl reductase mutants for lipoic acid intermediates, offering supply chain stability and cost reduction.
Patent CN101857887A reveals a cell-free extract method for high-purity aryl alcohols, offering significant cost and time advantages for pharmaceutical manufacturing.
Patent CN106701698B reveals high-efficiency SsCR enzyme for chiral alcohol synthesis. Achieves 99.9% ee and 500mmol/L substrate concentration for scalable manufacturing.
Patent CN113652408B reveals mutant enzyme for high-purity intermediate. Offers supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.